Galectin Therapeutics (GALT) Gains Again on Takeover, NASH Trial Speculation

September 21, 2016 10:53 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Galectin Therapeutics (NASDAQ: GALT) is surging higher again as speculators reprice NASH stocks following Allergen's (NYSE: AGN) takeover of Tobira (NASDAQ: TBRA) yesterday. Today, on its call, Allergan's CEO said Tobira was a 'very competitive situation'

Yesterday, H.C. Wainwright analyst Ed Arce told StreetInsider that GALT has the best read-through given its anti-fibrosis NASH drug GR-MD-02. The Company expects to report the top line results from a Phase 2 clinical trial by the end of the month.

Shares of GALT are up 31%.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Rumors, Trader Talk

Related Entities

H.C. Wainwright, Ed Arce

Add Your Comment